Non-Erosive Gastro-Esophageal Reflux Disease
Gastroenterology
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Phathom PharmaceuticalsFLORHAM PARK, NJ
2 programs1
1
VonoprazanPhase 31 trial
VonoprazanPhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Phathom PharmaceuticalsVonoprazan
Phathom PharmaceuticalsVonoprazan
Clinical Trials (2)
A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
Start: Jan 2022Est. completion: May 2023
Phase 3Completed
A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease
Start: Mar 2021Est. completion: Jan 2022
Phase 2Completed
Related Jobs in Gastroenterology
Specialty Representative, Gastroenterology – Minneapolis, Minnesota
AbbVie
Remote
12h ago
Head of Drug Product Development
Ironwood Pharmaceuticals
Boston, Massachusetts, United States
13h ago
$246K - $287K/yr
Regulatory Affairs Associate
Ferring Pharmaceuticals
Istanbul, Turkey
Yesterday
Key Account Director, Diagnostics and Research
Tempus
Remote
Yesterday
$150K - $200K/yr
Senior Sterilization Validation Engineer (m/f/d)
Johnson & Johnson
Beerse, Antwerp, Belgium
Yesterday
Senior Financial Analyst - Supply Chain Finance & Transformation (m/f/d)
Johnson & Johnson
Norderstedt, Schleswig-Holstein, Germany
Yesterday
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space